Till Capital Announces Appointment of Dr. Terry Rickard as

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Till Capital Announces Appointment of Dr. Terry Rickard as Interim CEO

HAMILTON, Bermuda, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Till Capital Ltd. (NASDAQ: TIL ) (TSX.V:TIL) (the “ Company ” or “ Till ”), a Bermuda domiciled company, announces the appointment of Dr. Terry Rickard as Interim Chief Executive Officer effective immediately.  Dr. Rickard is presently the Director of Quantitative Research for Till Management Company and serves on Till’s Board of Directors.    

Dr. Rickard has 44 years of experience in advanced technology and financial organizations.  He has been an executive and a director of several private companies as well as a public reporting company. He was President and later Chief Scientific Officer of OptiMark Technologies, Inc. and served on its board. He was a co-inventor of the OptiMark transaction matching system and was instrumental in the development of this company from a start-up enterprise to an operating entity on the Pacific Stock Exchange, the Nasdaq market and the Osaka Securities Exchange. Before that, he was President of the brokerage firm Mitchum, Jones & Templeton. He received a Ph.D. degree in Engineering Physics from the University of California, San Diego, in 1975.

William A. Lupien has stepped down as Interim CEO for personal reasons and to focus his attention on his duties as Chief Investment Officer for the Company.  Mr. Lupien remains a member of the board of directors of the company.

Reported by:

John T. Rickard Interim CEO

(208) 635-5415

Till Capital Ltd.

Till Capital Ltd. is a Bermuda-domiciled company with two wholly-owned subsidiaries, Omega Insurance Holdings Inc. and Resource Re Ltd.  Omega Insurance Holdings Inc. owns Omega General Insurance Company, a Canadian insurance company offering innovative and customized insurance industry solutions, including fronting and run-off services for insurers/reinsurers, within the Canadian marketplace.  Omega Insurance Holdings Inc. also operates Focus Group Inc., a consulting and project management company servicing the local and international needs of its Property Casualty Insurance clients. Resource Re Ltd. is a Bermuda-domiciled reinsurance company regulated by the Bermuda Monetary Authority with a Class 3A insurance license directed to underwrite reinsurance policies within a long term investment strategy. Through its regulated subsidiaries, the Company has been structured to produce underwriting profits as well as above average returns on assets under management.

For additional information:

Till Capital Ltd. Monique Hayes  (208) 699-6097 info@tillcap.com    www.tillcap.com  

Cautionary Note At this time, the Company has no current plans to provide earnings guidance due to the volatility of investment returns.

The Till Capital shares are restricted voting shares, whereby no single shareholder of Till Capital is able to exercise voting rights for more than 9.9% of the voting rights of the total issued and outstanding Till Capital shares (the “ 9.9% Restriction ”). However, if any one shareholder of Till Capital beneficially owns, or exercises control or direction over, more than 50% of the issued and outstanding Till Capital shares, the 9.9% Restriction will cease to apply to the Till Capital shares.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy any securities of Till Capital or any other securities, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. Trading in the securities of Till Capital should be considered speculative.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the Bermuda Monetary Authority accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward Looking Information Except for statements of historical fact, this news release contains certain “forward-looking information” within the meaning of applicable securities laws. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995, and generally can be identified by phrases such as “plan”, “except”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “will”, “could” and other similar words, or statements that certain events or conditions “may” occur. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, Till Capital assumes no obligation to update forward-looking information should circumstances or management’s estimates or opinions change.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 79

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 421

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Updated Category News Views 72

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 140

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 93

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 312

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 87

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading

Top 5 Most Recently Viewed Articles

Kohl's Stock Plummets Amid Retail Challenges and Restructuring

Updated Category News Views 589

Kohl's Corporation Faces Significant Challenges Kohl's Corporation (NYSE: KSS) has recently seen its stock plummet to a concerning 52-week low of $13.61. This decline paints a grim picture of the current retail environment, where shifting consumer habits and fierce competition play a pivotal role. Priced at just 0.4 times book value and boasting a generous 14.5% dividend...

Continue Reading
Rapid Micro Biosystems Achieves Record Growth and Future Outlook

Updated Category News Views 136

Financial Performance Highlights for Rapid Micro Biosystems Rapid Micro Biosystems, Inc. (NASDAQ: RPID) has announced impressive results for the fourth quarter and the entire fiscal year of 2024. The company recorded a total revenue of $8.2 million in the fourth quarter, marking a 30% increase compared to the same period in 2023. Likewise, the full year revenue reached...

Continue Reading
ALZpath and Siemens Team Up for Advanced Alzheimer's Testing

Updated Category News Views 265

ALZpath and Siemens Healthineers Form Strategic Partnership ALZpath is thrilled to announce a significant licensing agreement with Siemens Healthineers. This collaboration marks a pivotal enhancement in the accessibility of diagnostic testing for Alzheimer's disease. The agreement involves the use of ALZpath's proprietary pTau217 antibody, a remarkable tool for...

Continue Reading
Generate:Biomedicines Showcases Promising Results for GB-0895

Updated Category News Views 495

Results from Phase 1 Trials of GB-0895 Unveiled Generate:Biomedicines is making notable headlines with its innovative drug GB-0895. This cutting-edge treatment is an ultra-high affinity anti-TSLP monoclonal antibody, specifically designed for individuals grappling with asthma. With a unique formulation, GB-0895 offers a prolonged half-life and sustained pharmacological...

Continue Reading
Driving Growth in Natural Stone Market and Its Future

Updated Category News Views 226

Steady Growth in the Natural Stone Market The natural stone market is on a promising upward trajectory, predicted to rise from USD 37.89 billion to USD 47.63 billion by a future date, indicating a compound annual growth rate (CAGR) of 4.68%. Various factors are driving this growth, most notably the intense infrastructure investment blooming worldwide. The construction...

Continue Reading